Mevion Medical Systems To Supply Vietnam’s First Proton Therapy System To Tam Anh General Hospital
KUALA LUMPUR, May 28 (Bernama) -- Mevion Medical Systems has signed a definitive purchase agreement with Tam Anh General Hospital to supply the MEVION S250-FIT Proton Therapy System, marking what is expected to become Vietnam’s first proton therapy system.
According to a statement, the system is scheduled to become operational as early as late 2027 at Tam Anh’s new facility in Phu My Hung, Vietnam, following recent regulatory approvals for Mevion’s proton therapy systems in the country.
Mevion Medical Systems chief executive officer and president, Tina Yu said the partnership supports the company’s efforts to expand access to advanced cancer care globally.
Meanwhile, Tam Anh General Hospital Group chairman of the board of directors, Ngo Chi Dung said the acquisition marked a significant step in Vietnam’s adoption of advanced oncology technologies and reflected the hospital group’s long-term investment strategy in healthcare services.
The project is being facilitated by TD Tech Company, Mevion’s distributor in Vietnam, and forms part of broader efforts to expand access to advanced cancer treatment technologies in Southeast Asia.
The installation is expected to expand domestic access to proton therapy treatment in Vietnam, as the country joins a growing number of markets adopting advanced cancer treatment technologies.
Proton therapy is regarded as an advanced form of radiation treatment that enables targeted delivery of radiation to tumours while reducing exposure to surrounding healthy tissues. The treatment is often used in selected complex tumour cases and paediatric cancers.
Mevion said the MEVION S250-FIT system is designed to simplify deployment of proton therapy through installation in standard radiation therapy vaults, reducing construction requirements and shortening implementation timelines compared with conventional proton therapy facilities.
The system will also incorporate upright patient positioning technology from Leo Cancer Care and treatment planning capabilities from RaySearch Laboratories.
-- BERNAMA